PUBLISHER: The Business Research Company | PRODUCT CODE: 1948371
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948371
Tumor ablation therapy devices are minimally invasive tools used to treat tumors, typically in the kidney, liver, and lung. These devices utilize different techniques to target and destroy cancerous cells while safeguarding the surrounding healthy tissue.
The primary technologies utilized in tumor ablation therapy devices include radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and other related methods. Irreversible electroporation (IRE) is an innovative technique within tumor ablation therapy, involving the application of micro to millisecond electrical pulses to undesired tissue, which results in the induction of cell necrosis through irreversible cell membrane permeabilization. Treatments using these devices can take the form of surgical procedures, laparoscopic interventions, or percutaneous methods, and are applicable in the treatment of various types of cancer, including kidney, liver, breast, lung, prostate, and others. The end-users of tumor ablation therapy devices encompass hospitals, oncology clinics, and other healthcare facilities.
Tariffs are influencing the tumor ablation therapy devices market by increasing costs of imported generators, probes, imaging components, cryogenic systems, and electronic controls. Hospitals and oncology centers in North America and Europe are most affected due to reliance on imported high-value medical equipment, while Asia-Pacific faces higher production and export costs. These tariffs are increasing treatment system prices and extending procurement timelines. However, they are also driving localized device manufacturing, regional assembly operations, and innovation in cost-efficient ablation technologies.
The tumor ablation therapy devices market research report is one of a series of new reports from The Business Research Company that provides tumor ablation therapy devices market statistics, including tumor ablation therapy devices industry global market size, regional shares, competitors with a tumor ablation therapy devices market share, detailed tumor ablation therapy devices market segments, market trends and opportunities, and any further data you may need to thrive in the tumor ablation therapy devices industry. This tumor ablation therapy devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tumor ablation therapy devices market size has grown rapidly in recent years. It will grow from $0.82 billion in 2025 to $0.95 billion in 2026 at a compound annual growth rate (CAGR) of 15.0%. The growth in the historic period can be attributed to increasing cancer incidence rates, expansion of oncology treatment centers, rising adoption of minimally invasive therapies, availability of advanced imaging technologies, growing preference for organ-preserving treatments.
The tumor ablation therapy devices market size is expected to see rapid growth in the next few years. It will grow to $1.61 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing investments in precision oncology, rising demand for outpatient cancer treatments, expansion of advanced ablation technologies, growing integration of imaging and therapy systems, increasing focus on personalized cancer care. Major trends in the forecast period include increasing adoption of minimally invasive tumor ablation procedures, rising use of image-guided ablation systems, growing demand for organ-specific ablation technologies, expansion of percutaneous treatment approaches, enhanced focus on precision oncology.
The tumor ablation therapy devices market is experiencing growth driven by the increasing prevalence of cancer. Cancer is a leading cause of mortality, with approximately 1 in 6 deaths worldwide attributed to this disease. Tumor ablation therapy is a minimally invasive procedure widely used to treat various types of tumors, including those in the lung, liver, kidney, and bones. For example, in 2023, the American Cancer Society Inc., a US-based non-profit health organization, estimates that the US will see around 1,958,310 new cancer cases, an increase compared to the more than 1,918,030 new cancer cases in 2022. This procedure offers an effective treatment option, particularly for patients who have not responded to chemotherapy or radiotherapy, thus supporting the growth of the tumor ablation therapy devices market.
Major companies operating in the tumor ablation therapy devices market are focusing on developing minimally invasive therapies to gain a competitive edge. Minimally invasive therapy is widely used in tumor ablation as it enables precise and effective treatment while minimizing damage to surrounding healthy tissues. For instance, in August 2023, Francis Medical Inc., a US-based provider of minimally invasive treatment solutions for prostate, kidney, and bladder cancer, received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Vanquish minimally invasive water vapor ablation therapy. This designation is intended to accelerate the device's development and regulatory review, potentially enabling faster patient access. Vanquish uses the thermal energy contained in a small amount of sterile water vapor to deliver targeted treatment to cancerous tissue through a simple transurethral procedure. The therapy is designed to effectively destroy cancer cells while preserving nearby structures, thereby reducing the risk of severe side effects commonly associated with conventional prostate cancer treatments.
In October 2024, ExcelFin Acquisition Corp, a US-based publicly traded special purpose acquisition company, merged with Betters Medical Investment Holdings Limited (Baird Medical) for an undisclosed amount. Through this merger, ExcelFin plans to take Baird Medical public and support its growth strategy, allowing the company to expand its microwave ablation (MWA) technology portfolio and accelerate its penetration into the U.S. and global markets. Betters Medical Investment Holdings Limited is a China-based medical device company that develops microwave ablation systems for minimally invasive tumor treatment.
Major companies operating in the tumor ablation therapy devices market are Galil Medical Inc., Misonix Inc., HealthTronics Inc., AngioDynamics Inc., Boston Scientific Corporation, Medtronic plc, EDAP TMS S.A., NeuWave Medical Inc., BVM Medical Limited, Erbe Elektromedizin GmbH, Theraclion, INTIO Inc., Olympus Corporation, Stryker Corporation, Merit Medical Systems Inc., Insightec Ltd., Terumo Corporation, Monteris Medical Corporation, IceCure Medical Ltd., Profound Medical Inc., Alpinion Medical Systems Co. Ltd., Sonacare Medical, Hologic Inc., Endocare Inc., Bovie Medical Corporation,
North America was the largest region in the tumor ablation therapy devices market in 2025. Asia-Pacific was the second largest region in the tumor ablation therapy devices market. The regions covered in the tumor ablation therapy devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the tumor ablation therapy devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The tumor ablation therapy devices market consists of sales of radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others that are used for tumor ablation therapies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tumor Ablation Therapy Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses tumor ablation therapy devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for tumor ablation therapy devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tumor ablation therapy devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.